Head to head
CJC-1295 / Ipamorelin against Tesamorelin / Ipamorelin
Two vendor blends built on the same idea, a GHRH analogue plus a ghrelin mimetic. The difference is that one of the GHRH halves is an FDA-approved drug with phase 3 data and the other is not approved anywhere. Neither combination has been studied.
Column A
CJC-1295 / IpamorelinCJC-1295 and Ipamorelin blend (GHRH analogue plus ghrelin mimetic)
The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both.
Column B
Tesamorelin / IpamorelinTesamorelin and Ipamorelin blend (approved GHRH analogue plus ghrelin mimetic)
The clinic version of the growth hormone blend, pairing the one GHRH analogue with FDA approval against 806 patients of Phase 3 data with a ghrelin mimetic whose single human trial missed its endpoint. No study has tested the two together. On the common 5 mg plus 5 mg vial, reaching the 2 mg tesamorelin dose that produced the approved result also delivers 2 mg of ipamorelin, roughly seven to ten times the dose ipamorelin is used at alone.
Side by side, on the facts we can check
| Attribute | CJC-1295 / Ipamorelin | Tesamorelin / Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Not approved. Neither component is an approved drug, and the combination has never been submitted or studied. | Not approved as a blend. Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy; ipamorelin is not approved and no combination product exists. |
| Half-life | Not one number. The two components clear on completely different timescales, one within a few hours and the other over about a week. | Not one number. Both components clear within hours, but not at the same rate, and neither has been measured in the presence of the other. |
| Molecular weight | Mixture; CJC-1295 with DAC about 3,647.2 Da, ipamorelin 711.85 Da | Mixture; tesamorelin 5,135.9 Da, ipamorelin 711.85 Da |
| Mechanism | Two receptors on the same pituitary cell. CJC-1295 activates the GHRH receptor, raising the amplitude of growth hormone pulses; albumin binding through the Drug Affinity Complex extends that signal for days in the DAC version. Ipamorelin activates the growth hormone secretagogue receptor GHS-R1a, the ghrelin receptor, which both releases growth hormone and suppresses somatostatin tone. Combining a GHRH agonist with a GHS-R agonist produces a larger pulse than either alone in human testing, though that testing used GHRH itself with GHRP-6, not this pair. | Tesamorelin activates the pituitary GHRH receptor, raising the amplitude of endogenous growth hormone pulses while preserving hypothalamic feedback, which is the property that let it reduce visceral fat without the effects of giving growth hormone directly. Ipamorelin activates the ghrelin receptor GHS-R1a on the same cell, a separate pathway that also releases growth hormone and reduces somatostatin tone. The proposed rationale is that two different receptors produce a larger pulse than either alone, which is true of the GHRH plus GHRP class in acute human testing and untested for this specific pair. |
| Human studies cited | 3 | 5 |
| Legal status, US | Not approved; research use only | No approved blend; tesamorelin alone is approved as Egrifta |
Frequently asked questions
What is the difference between CJC-1295 / Ipamorelin and Tesamorelin / Ipamorelin?
CJC-1295 / Ipamorelin: The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both. Tesamorelin / Ipamorelin: The clinic version of the growth hormone blend, pairing the one GHRH analogue with FDA approval against 806 patients of Phase 3 data with a ghrelin mimetic whose single human trial missed its endpoint. No study has tested the two together. On the common 5 mg plus 5 mg vial, reaching the 2 mg tesamorelin dose that produced the approved result also delivers 2 mg of ipamorelin, roughly seven to ten times the dose ipamorelin is used at alone.
Which has stronger research evidence, CJC-1295 / Ipamorelin or Tesamorelin / Ipamorelin?
This database does not grade compounds. It counts what was run in people: 3 of the 5 studies cited on the CJC-1295 / Ipamorelin profile were human work, against 5 of 6 for Tesamorelin / Ipamorelin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are CJC-1295 / Ipamorelin and Tesamorelin / Ipamorelin FDA-approved?
CJC-1295 / Ipamorelin: Not approved. Neither component is an approved drug, and the combination has never been submitted or studied.. Tesamorelin / Ipamorelin: Not approved as a blend. Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy; ipamorelin is not approved and no combination product exists..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.